AngioDynamics reports FY2026 Q4 pro forma sales $86.6M (+8% YoY); Med Tech growth 16.7%

ANGIODYNAMICS INC

Q4 FY2026 pro forma net sales $86.6M (+8.0% YoY); Med Tech $41.8M (+16.7%), Med Device $44.8M (+1.1%).
Full year pro forma net sales $320.2M (+9.4%); GAAP net loss $36.7M ($0.88 loss per share); adjusted EBITDA $13.2M.
FY2027 guidance: net sales $336M-$341M, Med Tech growth 12-15%, adjusted EBITDA $13M-$16M, adjusted EPS ($0.29)-($0.24).
Clinical milestones: FDA IDE approvals for APEX-Return, PAVE, RELIEF studies; Palmetto GBA LCD for NanoKnife IRE in prostate/liver cancer.
Ended FY2026 with $53.9M cash, debt-free; tariff headwinds $4.8M in FY2026, expected similar in FY2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.